参考文献
PubMed=758928; DOI=10.1038/bjc.1979.3
Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y., Yasumoto K.
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Br. J. Cancer 39:15-23(1979)
DOI=10.5795/jjscc.24.451
Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y.
Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.
Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985)
PubMed=4094096; DOI=10.1093/oxfordjournals.jjco.a039097
Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J., Hoshi A., Chen K.-M., Hamburger A.W.
Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.
Jpn. J. Clin. Oncol. 15:637-644(1985)
PubMed=1847845; DOI=10.1007/BF00685110
Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N.
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Cancer Chemother. Pharmacol. 27:263-270(1991)
PubMed=1737336
Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K.
Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.
Cancer Res. 52:775-781(1992)
PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)
PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)
PubMed=9538136; DOI=10.3892/ijo.12.5.1103
Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H., Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.
Variable expression on lung cancer cell lines of HLA-A2-binding MAGE- 3 peptide recognized by cytotoxic T lymphocytes.
Int. J. Oncol. 12:1103-1109(1998)
PubMed=10536175; DOI=10.3892/ijo.15.5.927
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Int. J. Oncol. 15:927-934(1999)
PubMed=11005564; DOI=10.1038/sj.neo.7900094
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)
PubMed=11078804; DOI=10.3892/ijo.17.6.1187
Takenaka K., Shibuya M., Takeda Y., Hibino S., Gemma A., Ono Y., Kudoh S.
Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line.
Int. J. Oncol. 17:1187-1194(2000)
PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331
Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Cancer Res. 65:7276-7282(2005)
PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339
Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Cancer Res. 67:2046-2053(2007)
PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x
Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K.
Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.
Cancer Sci. 98:1048-1054(2007)
PubMed=19472407; DOI=10.1002/humu.21028
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)
PubMed=19799608; DOI=10.1111/j.1349-7006.2009.01351.x
Kuroda K., Takenoyama M., Baba T., Shigematsu Y., Shiota H., Ichiki Y., Yasuda M., Uramoto H., Hanagiri T., Yasumoto K.
Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.
Cancer Sci. 101:46-53(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)
PubMed=22313637; DOI=10.4161/cbt.19238
Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Cancer Biol. Ther. 13:369-378(2012)
PubMed=23733853; DOI=10.1101/gr.152322.112
Jia P., Jin H., Meador C.B., Xia J., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z., Pao W.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Genome Res. 23:1434-1445(2013)
PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477
Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
J. Proteome Res. 14:3658-3669(2015)
PubMed=26554430; DOI=10.1021/acs.analchem.5b03639
Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Anal. Chem. 87:12016-12023(2015)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=28290473; DOI=10.1038/srep44021
Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y., Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C., Chen Y.-J.
Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer.
Sci. Rep. 7:44021-44021(2017)
PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=34320349; DOI=10.1016/j.celrep.2021.109441
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441.1-109441.22(2021)
